Loading clinical trials...
Loading clinical trials...
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Conditions
Interventions
ASP2151
valacyclovir
+1 more
Locations
25
United States
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
Los Angeles, California, United States
Sacramento, California, United States
San Diego, California, United States
Start Date
June 21, 2007
Primary Completion Date
August 12, 2008
Completion Date
August 12, 2008
Last Updated
December 7, 2017
NCT04950712
NCT02852876
NCT00405821
NCT00076232
NCT00122525
NCT00158483
Lead Sponsor
Astellas Pharma Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions